Mp79-18 Ex-Vivo Evaluation of Intraprostatic Tracer Distribution of Targeted Versus Template Perineal Injection of Free Indocyanine Green for Fluorescence Targeted Pelvic Lymph Node Dissection (F-T Plnd) in Prostate Cancer

Abstract

The median follow-up of our cohort was 52.7 months. We found large differences in BCR between all grade groupings based on both the biopsy and surgical grading. The 5-year actuarial BCR for grade groups 1-5 based on the biopsy grade were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, respectively (p<0.00001). Similarly, the 5-year actuarial BCR based on the surgical grade was 96.1%, 93.0%, 74.0%, 64.4%, and 49.9% for grade groups 1-5, respectively (p<0.00001). Based on the biopsy grade, the hazard ratios relative to grade group 1 were 2.1, 4.8, 6.9, and 10.6 for groups 2, 3, 4, and 5, respectively, and for surgical grade were 2.3, 7.3, 10.4, and 18.9. When adjusting for T-stage, pre-operative PSA, and year of treatment the new grade grouping system remained highly prognostic. The five-grade group system had a higher prognostic discrimination compared to the commonly used 3-tier system (i.e. Gleason score 6, 7, and 8-10).CONCLUSIONS: In an independent surgical cohort, we have validated the prognostic benefit of the 2015 prostate cancer 5-tier grade grouping system in respect to BCR. The benefits of the new grade groupings are numerous for both patients and clinicians to improve prognostic staging systems and risk stratification systems.